| |
| | [No title] |
 | | After a Festo analysis, the court held that prosecution history estoppel prevented Glaxo from asserting that HPC in the accused Impax tablet was an equivalent of HPMC and, thus, held that the Impax composition did not infringe the claims that had been amended, affirming the lower court decision. |
 | | Glaxo argued, however, that prosecution history estoppel should not apply to claim 1 of the patent, which was filed with the HPMC limitation and not subject to narrowing amendments during prosecution. |
 | | Thus, prosecution history estoppel may apply even to unamended claims, further leveling whatever barriers might have existed to the use of estoppel to limit the doctrine of equivalents. |
| www.aplf.org /mailer/issue165.html (506 words) |
|